Did Vukasin Paunovich pay a price per share for the LifeStance (LFST) RSU grant?

The RSU grant to Vukasin Paunovich shows a transaction price of $0.0000 per share, indicating it was an equity award rather than a market purchase. Such grants are usually part of executive compensation and do not involve the executive paying cash for the shares at grant.

LifeStance CTO granted 86,331 RSUs

Paunovich Vukasin reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 03/09/2026 - 08:11 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Paunovich Vukasin reported acquisition or exercise transactions in this Form 4 filing.

LifeStance Health Group, Inc. Chief Technology Officer Vukasin Paunovich was granted 86,331 shares of common stock in the form of restricted stock units (RSUs) on March 5, 2026. Each RSU represents a right to receive one share of common stock, increasing his directly held stake to 264,902 shares after the award.

Insider Trade Summary

Grant/Award: 86,331 shares

Grant/Award 1 txn

Insider Paunovich Vukasin

Role Chief Technology Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	86,331	$0.00	$0.00

Holdings After Transaction: Common Stock — 264,902 shares (Direct)

Footnotes (1)

F1. Includes 86,331 restricted stock units ("RSUs") granted on March 5, 2026. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did LifeStance Health Group (LFST) report for Vukasin Paunovich?

LifeStance Health Group reported that Chief Technology Officer Vukasin Paunovich received a grant of 86,331 restricted stock units. These RSUs were awarded on March 5, 2026 and each unit represents a contingent right to receive one share of the company’s common stock.

How many LifeStance Health (LFST) shares does Vukasin Paunovich hold after this Form 4?

After the March 5, 2026 award, Vukasin Paunovich beneficially owns 264,902 shares of LifeStance common stock. This total includes the 86,331 restricted stock units granted, which each correspond to one share of common stock upon settlement, subject to applicable conditions.

What is the nature of the 86,331 RSUs granted to the LifeStance (LFST) CTO?

The 86,331 units are restricted stock units, each representing a contingent right to receive one share of LifeStance common stock. They were granted as an equity award, not purchased on the market, and typically vest over time or upon meeting specified service or performance conditions.

Does the LifeStance (LFST) Form 4 show a stock sale by the CTO?

The Form 4 does not report any stock sale by the CTO. It records only an acquisition coded as a grant or award of 86,331 restricted stock units, which increased his total beneficial ownership to 264,902 shares of LifeStance common stock after the reported transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Paunovich Vukasin

(Last)

(First)

(Middle)

C/O LIFESTANCE HEALTH GROUP, INC.

4800 N. SCOTTSDALE ROAD, SUITE 2500

(Street)

SCOTTSDALE

85251

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
LifeStance Health Group, Inc. [ LFST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Technology Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/05/2026		A		86,331⁽¹⁾	A	$0	264,902	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Includes 86,331 restricted stock units ("RSUs") granted on March 5, 2026. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

	By: /s/ Ryan Pardo, Attorney-in-Fact	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR